XTI Aerospace Appoints Prominent Aviation Industry Insider Jonathan G. Ornstein to its Board of Directors, Signaling Accelerated Push for Drone Leadership and M&A-Driven Growth
Prnewswire· 2026-02-04 13:30
Ornstein will serve as an independent director and chair the Board's Nominating and Corporate Governance Committee. He will also serve on the Board's Audit and Compensation Committees. About XTI Aerospace, Inc. XTI Aerospace, Inc. (Nasdaq: XTIA) is an aerospace technology company focused on the advancement of vertical flight. Through its Drone Nerds business, acquired in November 2025, XTI is a premier provider of unmanned aircraft systems ("UAS"), solutions, services and hardware. Through its XTI Aircraft ...
CAVU Resources, Inc. (OTC:CAVR) Provides Update on Timeline for Proposed Merger with Post Bid Ship, Inc.
Accessnewswire· 2026-02-04 13:30
TULSA, OKLAHOMA / ACCESS Newswire / February 4, 2026 / CAVU Resources, Inc . ("CAVR" or the "Company"), OTC, today issued an update regarding the timeline for its proposed spin-out and merger with Post Bid Ship, Inc. and PBS Recon, Inc. The Company announced that the previously anticipated January 31, 2026, target for establishing a definitive record date has been deferred. ...
AdvisorShares Marks One-Year Anniversary of the First ETF Dedicated to the HVAC Industry
Prnewswire· 2026-02-04 13:30
The AdvisorShares HVAC and Industrials ETF (Ticker: HVAC) has outperformed the S&P 500 Index since inception as demand for HVAC infrastructure expands across data centers, commercial construction and residential markets. BETHESDA, Md., Feb. 4, 2026 /PRNewswire/ -- AdvisorShares, a leading sponsor of actively managed exchange-traded funds (ETFs), today marks the one-year anniversary of the AdvisorShares HVAC and Industrials ETF (Ticker: HVAC). HVAC launched on February 3, 2025, as the first and only ETF dedi ...
Ispire-Backed IKE Tech Invited to Participate in FDA Roundtable on PMTA Submissions
Prnewswire· 2026-02-04 13:30
Invitation-Only Forum Underscores FDA Recognition of IKE Tech as a Key Stakeholder and Highlights the Strategic Role of Age-Gating Technology in the Future of ENDS Regulation and Compliance LOS ANGELES, Feb. 4, 2026 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ: ISPR), a trailblazer in vaping technology and precision dosing, announced that IKE Tech LLC ("IKE Tech" or "IKE"), a joint venture that includes Ispire as a founding partner, has been invited by the U.S. Food and Drug Ad ...
ARKO Corp. Opens New Handy Mart Store Featuring its New fas craves Food Concept
Globenewswire· 2026-02-04 13:30
Handy Mart #1 New-to-Industry store elevates retail experience Handy Mart #2 Wide array of product offerings fas craves #1 Delicious, grab and go food fas craves #2 New expanded menu for both food and beverage fas REWARDS Free loyalty program to save at the pump RICHMOND, Va., Feb. 04, 2026 (GLOBE NEWSWIRE) -- ARKO Corp. (Nasdaq: ARKO), a Fortune 500 company and one of the largest convenience store operators in the United States, is excited to announce the opening of its newest Handy Mar ...
Fitell Corporation Appoints AI and Robotics Executive Jack Zeng as Head of Technology at 2F Robotics to Accelerate Development and Commercialization Strategy
Globenewswire· 2026-02-04 13:30
Sydney, Australia, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Fitell Corporation (NASDAQ: FTEL) (“Fitell” or the “Company”) announced today the appointment of Jack Zeng as the Head of Technology of 2F Robotics Pty Ltd, Fitell’s robotics-focused subsidiary. Before joining Fitell, Mr. Zeng has founded and scaled successful technology ventures and brought experience in building data analytics and intelligent agent solutions for major enterprise customers including Fortune 500 across Asia, spanning product research and ...
Biodexa Announces Exclusive License of Otsuka's OPB-171775, a potent Phase 1 ready Molecular Glue for GIST
Globenewswire· 2026-02-04 13:30
February 4, 2026 Biodexa Announces Exclusive License of Otsuka’s OPB-171775, a potent Phase 1 ready Molecular Glue for GIST Novel Mechanism of Action Shown to be Effective in TKI Resistant PDX Models Cardiff, UK – February 4, 2026 – Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of rare diseases with unmet medical needs, today announced the closing of an exclusive license with Otsuka Pharmaceutical Co., Lt ...
Biodexa Announces Exclusive License of Otsuka’s OPB-171775, a potent Phase 1 ready Molecular Glue for GIST
Globenewswire· 2026-02-04 13:30
February 4, 2026 Biodexa Announces Exclusive License of Otsuka’s OPB-171775, a potent Phase 1 ready Molecular Glue for GIST Novel Mechanism of Action Shown to be Effective in TKI Resistant PDX Models Cardiff, UK – February 4, 2026 – Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of rare diseases with unmet medical needs, today announced the closing of an exclusive license with Otsuka Pharmaceutical Co., Lt ...
Core Silver Significantly Expands Copper-Molybdenum Footprint at Laverdiere Through Soil Sampling
Accessnewswire· 2026-02-04 13:30
differ materially from those in such forward-looking statements. Risks and uncertainties include that the Company may not, due to environmental, technological and other factors, be successful in expanding the mineralization footprint of the Projects as planned; that the Company may be unable to implement its plans to further explore at the Silver Lime Project and the Laverdiere Project, as applicable; that certain exploration methods, including the Company's proposed exploration model for the Blue Property, ...
Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor
Globenewswire· 2026-02-04 13:30
Seasoned oncology drug development leader joins following early clinical proof-of-concept for WEE1 inhibitor, APR-1051DOYLESTOWN, Pa., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea” or the “Company”), a clinical-stage biopharmaceutical company developing innovative therapies that exploit cancer-specific vulnerabilities while minimizing damage to healthy cells, today announced the appointment of Eugene (Gene) Kennedy, MD, as Chief Medical Advisor. Dr. Kennedy joins Aprea a ...